Too Easy !! All of the above.. Regarding approval: They have already Failed Twice. This is their third attempt. They have had 41/2 years trying. Nice to have these so called shelf life ( longer) Temperature range greater . Pure Mithra Fornieri sales pitch. A Generic is exactly that a Generic. Identical !!!!! So Price is your only sales advantage. I never said FDA wouldn’t approve. The only Generic manufacturing winner is first to market. ( Obviously ) Dont forget Merck have their own Generic which is Nuvaring in different packaging. Cost for Mayne has been 41/2 years of wasted bloody time and Carrot Dangling!! There must also be R and D . Some of their 900 staff costs. ( Who really knows ??? My valuation for Myring now is Zip It may assist as another of Maynes contraceptive products in Bundle sales. We were Number 2 in USA Now 3-4 . Also Krugerrand I just read your profits min 2% market share. Your Maths I can’t quite follow. Your sums are close but not precise. You obviously have recently invested and arnt min negative territory Good for you. But truly Krugs FF from Mithra will probably be sentenced to prison . This is the same guy who dealt with our CEO. Let’s face the facts if Nextellis was the next big thing after 50 years of contraceptives why seriously would you appoint MYX as your Distributor in US. They had more to gain from Mayne than the reverse.
MYX Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)